Medicaid’s expenditures for newer pharmacotherapies for adults with disabilities by Shireman, Theresa I. et al.
  
 
    
     
     
     
       
      
     
    
      
      
     
   
     
     
   
   
       
 
 
     
     
    
     
     
    
       
    
     
     
     
       
     
       
      
      
     
    
    
     
    
      
    
      
Medicaid’s Expenditures for Newer Pharmacotherapies
for Adults with Disabilities 
Theresa I. Shireman, Ph.D., R.Ph., Jean P. Hall, Ph.D., Sally K. Rigler, M.D., M.P.H., and
 
Janice M. Moore, M.A., M.B.A., M.S.W.
 
Medicaid’s drug expenditures have grown 
at double-digit inflation rates since 2000. 
These prescription drug costs are important 
contributors to increasing health care costs 
for disabled persons. In spite of this knowl­
edge, little has been reported about specific 
patterns of medication use among disabled 
enrollees. We analyzed Kansas Medicaid 
data to describe trends in medication use 
patterns across 3 years among disabled ben­
eficiaries. The marked shifts toward newer 
medications and disproportionate contribu­
tions of newer, more expensive medications 
to overall prescription costs for antipsychot­
ics, antidepressants, anticonvulsants, anti­
ulcer medications, anti-inflammatory agents, 
and opioids have implications for both policy
and practice. 
intrODUCtiOn 
Prescription drug costs are an impor­
tant contributor to increasing health care 
costs for aged and disabled persons. Med­
icaid’s drug expenditures have grown 
at double-digit inflation rates since 2000 
(Baugh et al., 2004). Although prescription 
drug coverage for dually eligible beneficia­
ries transitioned to the Medicare Part D 
drug benefit on January 1, 2006, the pat­
tern of rising prescription drug costs for 
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dually eligible Medicaid recipients is likely 
to continue to affect public expenditures 
in a similar manner. In fiscal year 2000, 
the aged- and blind/disabled-eligibility 
groups accounted for 14.3 and 24.8 per­
cent, respectively, of Medicaid enrollment 
but 26.8 and 58.1 percent, respectively, 
of Medicaid prescription drug expen­
ditures (Baugh et al., 2004). Blind and 
disabled enrollees have seen the sharp­
est increases in payments for prescrip­
tion medications since 1990, growing at 
an annual rate of 20.1 percent compared 
to 13.5 percent for the elderly (Baugh
et al., 2004). 
Previously, we assessed the cost contri­
butions of newer pharmaceuticals to grow­
ing prescription expenditures for Kansas 
Medicaid’s aged enrollees during a 3-year 
period (Shireman et al., 2005). Although 
newer pharmaceuticals accounted for more 
than 50 percent of prescriptions in four of 
eight therapeutic classes, they accounted 
for a disproportionately higher rate of 
expenditures for five of those classes. 
Mean prescription prices rose during the 
3 years primarily due to the adoption of 
newer pharmaceuticals as the newer prod­
ucts were at least twice as expensive as 
older options in six of eight classes. 
Little has been reported about the spe­
cific patterns of medication use among 
Medicaid’s disabled enrollees. Since they 
constitute the most expensive Medicaid 
Program and have even more extreme 
medication expenditures than the elderly, 
we performed a similar analysis of newer 
versus older medication use patterns 
to help inform State policymakers. It is 
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reasonable to assume that this analysis 
will identify future areas of research into 
understanding medication use in a highly 
medicated population. 
We analyzed Kansas Medicaid data to 
describe trends in medication use patterns 
for seven therapeutic drug classes across 3 
years. We limited the analysis to disabled 
persons between the ages of 18 and 65 
who qualified for Social Security Income 
(SSI) benefits or were medically needy. We 
excluded other disabled groups who may 
have received Medicaid benefits, such as 
those awaiting SSI determination (Medi-
Kan). Our exploration was limited to the 
types of medications commonly used by 
this population. In particular, we evaluated 
the impact on Medicaid’s expenditures of 
shifts from older, less expensive medica­
tions to newer, more costly options within 
the same drug class. 
MetHODS 
Study Design 
The study design was a retrospective 
cross-sectional analysis reflecting three 
sequential, 1-year time periods. Due to 
the timing of the data extraction, the third 
time period only included 11 months of 
prescription claims. The methods were 
nearly identical to those applied in the 
analysis of newer medication adoption in 
an older Medicaid cohort (Shireman et al., 
2005). The only difference was the list of 
therapeutic classes included in the analysis
that follows. 
Sample Selection 
The sampling frame consisted of per­
sons enrolled at least 1 month between 
May 1999 and April 2002 in Kansas Med­
icaid’s SSI or medically needy disabled 
programs. The Department of Social and 
Rehabilitation Services (SRS) provided a 
10-percent random sample (n = 6,256) of 
the sampling frame (n = 62,651) to repre­
sent the study population. We eliminated 38 
cases with dates of death prior to May 1999, 
leaving a final baseline cohort of 6,218 per­
sons. Persons enrolled in managed care 
were excluded as their claims data would 
not be complete. 
Data extraction 
Using the beneficiary identification num­
bers, an SRS programmer extracted all paid 
and crossover claims from institutions, out­
patient service providers, pharmacies, and 
nursing homes for services rendered dur­
ing the three study periods. The benefi­
ciary-based claims files contained detailed 
information regarding services provided, 
including dates of service; diagnosis codes; 
procedures conducted or medications dis­
pensed; billing provider information; and 
payment amounts for Medicare, other third 
party payers, and Medicaid. The program­
mer also cleaned the claims data by remov­
ing reversals and duplicates and accounting 
for adjustments. In addition to the claims 
data, the programmer created an eligibility 
file that contained beneficiary information 
such as date of birth, date of death, race 
and ethnic class, sex, and monthly enroll­
ment indicators for each month during the 
period that the beneficiary was actively 
enrolled in Medicaid. 
We determined dual eligibility for Medic­
aid and Medicare by analyzing Medicaid’s 
inpatient and outpatient claims for Medi­
care payments. We pooled diagnosis codes 
from institutional, outpatient service, and 
nursing home claims for each individual, 
and determined the presence of major 
medical and mental health conditions 
through comorbidity flags based on diagno­
sis codes (Centers for Disease Control and 
Prevention, 2007) from the International 
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Classification of Diseases, Ninth Revision, 
Clinical Modification. 
Prescription Drug analysis 
We analyzed drug use patterns in the 
seven therapeutic classes accounting for 
the largest expenditures for the Kansas 
Medicaid disabled population: (1) antibiot­
ics, (2) antidepressants, (3) antipsychotics, 
(4) anticonvulsants, (5) anti-ulcer medica­
tions, (6) diabetes medications, and (7) 
analgesics. Due to differences in indica­
tions for use, we further divided analgesics 
into two categories: opioids and non-ste­
roidal anti-inflammatory drugs (NSAIDs). 
These therapeutic classes differed slightly 
from those examined in our prior analysis 
of aged Medicaid beneficiaries (Shireman 
et al., 2005). 
Drugs within each therapeutic class 
were separated into two subclasses, based 
on relative newness to the class at the time 
the medication was prescribed (Shire­
man et al., 2005). A physician and a clini­
cal pharmacist independently classified the 
individual drugs within each class, with a 
second physician adjudicating disagree­
ments. For most drug groups, newer and 
older designations were based on whether 
or not a generic form of the medication 
was available during the study timeframe. 
If the specific drug was available in generic 
form, then that drug was classified as old, 
regardless of whether a generic or brand 
name agent may have been ordered or 
dispensed. If only a trade-name agent was 
available during the study timeframe, then 
the medication was classified as new. 
For most drug groups, this categoriza­
tion paralleled clinically relevant drug char­
acteristics for grouping similar medications 
together. For example, antipsychotics were 
categorized as either older, typical anti-
psychotics (e.g., chlorpromazine and halo­
periodol) or newer, atypical antipsychotics 
(e.g., clozapine, risperidone, and olanzap­
ine). Similarly, we classified the tricyclic 
amines (TCAs), trazodone, and maprotiline 
as older antidepressants: selective sero­
tonin reuptake inhibitors (SSRIs), and other 
trade name only antidepressants (e.g., ven­
lafaxine and mirtazapine) constituted the 
newer antidepressants. For other therapeu­
tic classes, categories were derived based 
on clinically relevant distinctions, but which 
still paralleled older and newer treatment 
options. For example, opioid analgesics 
were categorized into the long-acting opi­
oids (e.g., MSContin, Oxycontin, and trans­
dermal fentanyl) or shorter-acting agents. 
Anti-ulcer agents were categorized into 
H2 receptor antagonists (H2RA) or pro­
ton-pump inhibitors (PPI), after excluding 
antacids and misoprostol. The final adjudi­
cated categories are shown in Table 1. 
Overall Use and Price Changes 
After selection and classification of the 
pertinent medications from the Medicaid 
pharmacy claims, we explored changes 
within therapeutic classes over the three 
study periods. First, we calculated utiliza­
tion changes within therapeutic categories 
based on the number of prescriptions per 
person-years of observation. We deter­
mined person-years of observation using 
the months of eligibility within each study 
period for each beneficiary. This unit of 
measure allowed us to document general 
trends in the use of each class over time. 
Secondly, we examined the mean pre­
scription price for agents in the subclass 
during each period. We included only the 
amounts paid by Medicaid. Dollar amounts 
were adjusted for inflation using the U.S. 
city average consumer price index for 
all items with 1999 as the base year (U.S. 
Department of Labor, 2007). Manufactur­
ers’ rebates were not considered in the 
prices since these were proprietary. 
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Table 1
�
Individual Medication Categorized as New or Old within Therapeutic Classes
�
Category 
	 Old	 New 
Antibiotics 
Acyclovir,	amoxicillin,	ampicillin,	cefaclor,	cefadroxil,	 
cefazolin,	cephalexin,	chloroquine,	clindamycin,	clotrimazole,	 
cloxacillin,	dapsone,	demeclocycline,	dicloxacillin,	 
doxycycline,	erthromycin,	gentamicin,	griseofulvin	microsize,	 
ketoconazole,	lincomycin,	mebendazole,	mefloquine,	 
methenamine,	metronidazole,	minocycline,	neomycin,	 
nitrofurantoin,	nystatin,	oxacillin,	penicillin,	rifampin,	 
sulfamethoxazole/trimethoprim,	sulfasalazine,	tetracycline,	 
tobramycin	sulfate,	trimethoprim,	vancomycin 
Anticonvulsants 
Carbamazepine,	clonazepam,	diazepam,	divalproex,	 
ethosuximide,	mephenytoin,	mephobarbital,	methsuximide,	 
phenytoin,	sustained	release	phenytoin,	primidone,	valproate,	 
valproic	acid 
Antidepressants 
Amitriptyline,	amoxapine,	clomipramine,	desipramine,	 
doxepin,	imipramine,	maprotiline,	nortriptyline,	phenelzine,	 
protriptyline,	trancyclomine,	trazodone 
Antidiabetic Agents 
Insulin,	chlorpropamide,	glipizide,	glyburide,	metformin 
Anti-Inflammatory Agents 
NSAIDS:	Diclofenac,	diflunisal,	choline	salicylate,	ketorolac,	 
ketoprofen,	naproxen,	sulindac,	indomethacin,	ibuprofen,	 
oxaprozin,	nabumetone,	meclofenamate,	mefenamic	acid,	 
meloxicam,	etodolac,	salsalate,	flurbiprofen,	piroxicam,	 
fenoprofen,	tolmetin 
Antipsychotics 
Chlorpromazine,	fluphenazine,	haloperidol,	lithium,	loxapine,	 
mesoridazine,	molindone,	perphenazine,	pimozide,	 
thioridazine,	thiothixene,	trifluoperazine 
Anti-Ulcer Medications 
H2	antagonist:	Cimetidine,	famotidine,	nizatidine,	ranitidine 
Opioids 
Short-acting	opioids:	Acetaminophen/aspirin/propoxyphene	 
with	codeine	or	hydrocodone,	butorphanol,	codeine,		 
fentanyl	transmucosal,	hydrocodone,	hydromorphone,	 
meperidine,	methadone,	morphine,	oxycodone,	 
propoxyphene,	tramadol 
Amoxicillin/clavulanate,	ampicillin/sulbactam,	azithromycin,	 
aztreonam,	carbenicillin,	cefdinir,	cefditoren,	cefepime,	 
cefixime,	cefpodoxime,	cefprozil,	ceftazidime,	ceftibuten,	 
ceftriaxone,	cefuroxime,	cephradine,	cinoxacin,	 
ciprofloxacin,	clarithromycin,	dirithromycin,	famciclovir,	 
fluconazole,	fosfomycin,	ganciclovir,	gatifloxacin,	grisofulvin	 
ultramicrosize,	itraconazole,	levofloxacin,	linezolid,	loracarbef,	 
moxifloxacin,	norfloxacin,	ofloxacin,	oseltamivir,	piperacillin/ 
tazobactam,	rimantadine,	sparfloxacin,	terbinafine,	ticarcillin/ 
clavulanate,	tobramycin	sodium	sulfate,	trovafloxacin,	 
valacyclovir,	valganciclovir,	zanamivir 
Felbamate,	gabapentin,	lamotrigine,	levetiracetam,	 
oxcarbazepine,	tiagabine,	topiramate,	zonisamide 
Bupropion,	citalopram,	fluoxetine,	fluvoxamine,	mirtazapine,	 
nefazodone,	paroxetine,	sertraline,	venlafaxine 
Acarbose,	glipizide	extended	release,	glyburide/metformin,	 
glimepiride,	insulin	glargine,	miglitol,	nateglinide,	pioglitazone,	 
repaglinide,	rosiglitazone,	troglitazone 
Cox-2	Selective:	Celecoxib,	rofecoxib,	valdecoxib 
Clozapine,	olanzapine,	quetiapine,	risperidone,	ziprasidone 
Proton	pump	inhibitor:	Esomeprazole,	lansoprazole,	 
omeprazole,	pantoprazole,	rabeprazole 
Long-acting	opioids:	Sustained	release	oxycodone,	 
sustained-release	morphine,	fentanyl	transdermal 
NOTES:	If	a	specific	drug	was	available	in	generic	form,	then	that	drug	was	classified	as	old.	If	only	a	trade-name	was	available	during	the	study	 
timeframe,	then	that	drug	was	classified	as	new. 
SOURCE:	Shireman,	T.I.,	University	of	Kansas	Medical	Center:	Analysis	of	Kansas	Medicaid	prescription	drug	claims	from	Kansas	Department	of	 
Social	and	Rehabilitation	Services,	2007. 
Market Share analysis market share, held by each subclass as a 
percent of total prescriptions for the class; 
The next set of outcomes related to new and (2) the market share held by each sub-
versus old drug use. Drugs within the class class as a percent of total expenditures for 
designations were compared with respect the class. 
to (1) the proportion of the market, or 
HealtH Care FinanCing review/Summer 2007/Volume 28, Number 4 34
      
      
      
     
     
     
       
      
       
      
      
    
       
      
    
     
     
     
 Table 2 
Description of Kansas Disabled Medicaid Enrollees with at Least 1 Month of Eligibility: 1999-2002 
	 May	1999-April	2000	 May	2000-April	2001	 May	2001-March	2002 
	 Number	of	 Percent	of	 Number	of	 Percent	of	 Number	of	 Percent	of 
Characteristic	 Subjects	 Subjects	 Subjects	 Subjects	 Subjects	 Subjects 
Total	Cohort	 4,075	 100	 4,231	 100	 4,208	 100 
Female	 2,261	 55.5	 2,321	 54.9	 2,341	 55.6 
Race/Ethnic 
White	 3,203	 78.6	 3,336	 78.8	 3,301	 78.4 
Black	 653	 16	 679	 16	 691	 16.4 
Hispanic-American	 94	 2.3	 100	 2.4	 96	 2.3 
Other	 125	 3.1	 116	 2.7	 120	 2.9 
Age	Mean	 43.1	 —	 43.8	 —	 44.3	 — 
(SD)	 (12.6)	 —	 (12.8)	 —	 (13.0)	 — 
Age	 
18–35	Years	 1,231	 30.2	 1,200	 28.4	 1,156	 27.5 
36–50	Years	 1,569	 38.5	 1,643	 38.8	 1,595	 37.9 
51–64	Years	 1,275	 31.3	 1,388	 32.8	 1,457	 34.6 
Dually	Eligible	Enrollee	 1,327	 32.6	 1,359	 32.1	 1,372	 32.6 
Eligibility	During	Period 
<	6	Months	 432	 10.6	 427	 10.1	 362	 8.6 
6-9	Months	 375	 9.2	 396	 9.4	 363	 8.6 
10-12	Months		 3,268	 80.2	 3,408	 80.5	 3,483	 82.8 
	 	 
Person	Years	of	Eligibility1	 3,587	 —	 3,735	 —	 3,778	 — 
Comorbidities 
Psychoses	 1,634	 40.1	 1,688	 39.9	 1,680	 39.9 
Hypertension	 806	 19.8	 854	 20.2	 861	 20.5 
Chronic	Lung	Diseases	 674	 16.5	 702	 16.6	 684	 16.3 
Mental	Retardation		 532	 13.1	 495	 11.7	 548	 13.0 
Diabetes	 491	 12.0	 560	 13.2	 568	 13.5 
Gastrointestinal	Disorders	 456	 11.2	 506	 12.0	 507	 12.0 
Depression	 390	 9.6	 437	 10.3	 424	 10.1 
Cancer	 362	 8.9	 363	 8.6	 345	 8.2 
Ischemic	Heart	Disease	 271	 6.7	 279	 6.6	 252	 6.0 
Mobility	Disorders	 241	 5.9	 272	 6.4	 254	 6.0 
Congestive	Heart	Failure	 240	 5.9	 235	 5.6	 218	 5.2 
Arrhythmias	 224	 5.5	 214	 5.1	 199	 4.7 
Cerebrovascular	Disease	 165	 4.0	 195	 4.6	 178	 4.2 
1Person	years	of	eligibility	is	a	summation	of	the	length	of	eligibility	for	each	Medicaid	enrollee	during	the	study	period. 
NOTE:	SD	is	standard	deviation. 
SOURCE:	Shireman,	T.I.,	University	of	Kansas	Medical	Center:	Analysis	of	Kansas	Medicaid	prescription	drug	claims	from	Kansas	Department	of	 
Social	and	Rehabilitation	Services,	2007. 
reSUltS 
In each study period, the analysis 
included in excess of 4,000 disabled adults 
(Table 2). Just over one-half were female 
(55 percent each year). Over three-quarters 
(78 percent) were White persons; Black 
persons were the most predominant minor­
ity group. The mean age was 43-44 years, 
and the highest proportion of enrollees (38 
percent) was between the ages of 36 and 
50. Nearly one-third of the cohort mem­
bers (32 percent) were dually eligible for 
Medicaid and Medicare. Eighty percent 
or more were eligible for 10-12 months
during each period, resulting in over 3,500 
person-years of observation per period. 
The most prevalent conditions among the 
cohort were psychosis (40 percent), hyper­
tension (20 percent), chronic lung diseases 
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Table 3 
Patterns of Drug Use Adjusted for Person-Years of Observation for Eight Therapeutic Classes 
for Kansas Medicaid Disabled Enrollees: 1999-2002 
	 Prescriptions/Person-Year 
Drug	Class	 May	1999-April	2000	 May	2000-April	2001	 May	2001-March	2002	 Percent	Change 
Antidepressants	 	 	 	 
New	(SSRI/Others)	 2.00	 2.30	 2.52	 26.0 
Old	(TCA)	 0.98	 0.97	 0.92	 -5.8 
Combined	 2.98	 3.27	 3.44	 15.5 
	 	 	 	 
Anticonvulsants	 	 	 	 
New	 0.53	 0.74	 0.92	 72.2 
Old	 2.42	 2.49	 2.35	 -3.0 
Combined	 2.95	 3.23	 3.26	 10.6 
	 	 	 	 
Opioids	 	 	 	 
New	(Long-Acting)	 0.23	 0.33	 0.34	 46.0 
Old	(Short-Acting)	 2.48	 2.43	 2.61	 5.1 
Combined	 2.72	 2.76	 2.95	 8.6 
	 	 	 	 
Antipsychotics	 	 	 	 
New	(Atypical)	 1.92	 2.12	 2.23	 15.9 
Old	(Typical)	 0.86	 0.75	 0.65	 -24.4 
Combined	 2.78	 2.87	 2.88	 3.5 
	 	 	 	 
Antibiotics	 	 	 	 
New	 1.04	 0.99	 1.02	 -1.2 
Old	 1.19	 1.11	 1.09	 -7.6 
Combined	 2.22	 2.09	 2.12	 -4.7 
Antidiabetic Agents	 	 	 	 
New	 0.41	 0.54	 0.66	 62.2 
Old	 1.03	 1.09	 1.04	 1.1 
Combined	 1.43	 1.62	 1.70	 18.4 
	 	 	 	 
Anti-Ulcer	 	 	 	 
New	(PPIs)	 1.03	 1.15	 1.18	 14.8 
Old	(H2RA)	 0.63	 0.52	 0.49	 -21.8 
Combined	 1.66	 1.68	 1.68	 1.0 
	 	 	 	 
Anti-Inflammatories	 	 	 	 
New	(Cox-2	Selective)	 0.46	 0.69	 0.73	 58.1 
Old	(NSAID)	 0.84	 0.70	 0.67	 -20.3 
Combined	 1.31	 1.39	 1.41	 7.5 
NOTES:	Figures	reflect	the	number	of	prescriptions	in	that	therapeutic	class	divided	by	all	cohort	members,	including	those	who	did	and	did	not	 
receive	such	a	prescription,	and	displayed	per	person-year	of	observation	to	adjust	for	different	periods	of	eligibility	for	each	individual.		SSRI	is	 
selective	serotonin	reuptake	inhibitor.	TCA	is	tricylic	amine.	PPI	is	proton	pump	inhibitor.	H2RA	is	histamine-2	receptor	antagonist.	NSAID	is		 
non-steroidal	anti-inflammatory	drug. 
SOURCE:	Shireman,	T.I.,	University	of	Kansas	Medical	Center:	Analysis	of	Kansas	Medicaid	prescription	drug	claims	from	Kansas	Department	of	 
Social	and	Rehabilitation	Services,	2007. 
(16 percent), diabetes (12-13 percent), 
mental retardation (12-13 percent), and 
gastrointestinal disorders (11-12 percent), 
as shown in Table 2. 
Table 3 displays the trends in prescrip­
tion utilization per person-year of obser­
vation for each of the drug classes. The 
classes with the highest use were antide­
pressants (3.44 prescriptions per person 
year, or RXs/PY), anticonvulsants (3.26 
RXs/PY), opioids (2.95 RXs/PY), and 
antipsychotics (2.88 RXs/PY). Overall 
drug use increased in all classes except 
for antibiotics which saw a 4.7-percent 
decline in prescriptions per person year. 
Newer agents accounted for a clear major­
ity of the increases: newer anticonvul­
sants increased by 72 percent, newer 
antidiabetic agents by 62 percent, newer 
anti-inflammatory agents by 58 percent, 
newer long-acting opioids by 46 percent, 
and newer antidepressants by 26 percent. 
The use of older agents declined in six of 
the eight classes: antibiotics, antipsychot­
ics, antidepressants, anticonvulsants, anti­
ulcer medications, and anti-inflammatory 
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Table 4
�
Changes in Mean Prescription Price for Eight Therapeutic Classes for Kansas Medicaid 

Disabled Enrollees: 1999-2002
�
	 Mean	Prescription	Price 
Drug	Class	 Period	1	 Period	2	 Period	3	 Percent	Change 
Antidepressants 
New	(SSRI/Others)	 $84.51		 $84.89		 $86.43		 2.3 
Old	(TCA)	 14.16	 10.99	 8.24	 -41.8 
Combined	 61.37	 62.92	 65.45	 6.7 
Anticonvulsants 
New	 139.34	 133.73	 136.15	 -2.3 
Old	 52.27	 49.28	 48.08	 -8.0 
Combined	 67.97	 68.58	 72.81	 7.1 
Opioids 
New	(Long-Acting)	 171.56	 234.85	 310.77	 81.1 
Old	(Short-Acting)	 20.81	 22.45	 22.89	 10.0 
Combined	 33.65	 47.96	 55.86	 66.0 
Antipsychotics 
New	(Atypical)	 182.39	 183.98	 191.35	 4.9 
Old	(Typical)	 31.80	 29.07	 29.59	 -6.9 
Combined	 135.76	 143.33	 154.74	 14.0 
Antibiotics 
New	 93.96	 93.37	 83.36	 -11.3 
Old	 17.35	 16.63	 16.68	 -3.9 
Combined	 53.07	 52.72	 48.88	 -7.9 
Antidiabetic Agents 
New	 77.86	 66.50	 69.55	 -10.7 
Old	 39.29	 42.31	 46.11	 17.4 
Combined	 50.22	 50.32	 55.21	 9.9 
Anti-Ulcer 
New	(PPIs)	 130.90	 123.20	 118.04	 -9.8 
Old	(H2RA)	 60.46	 50.99	 28.05	 -53.6 
Combined	 104.26	 100.64	 91.67	 -12.1 
Anti-Inflammatories	 
New	(Cox-2	Selective)	 80.27	 79.39	 83.87	 1.3 
Old	(NSAID)	 37.93	 34.64	 31.64	 -16.6 
Combined	 52.94	 56.84	 58.88	 11.2 
NOTES:	Combined	indicates	mean	price	for	entire	market	basket	including	new	and	old	agents.	Mean	prescription	prices	adjusted	for	inflation	 
to	1999	dollars.	SSRI	is	selective	serotonin	reuptake	inhibitor.	TCA	is	tricylic	amine.	PPI	is	proton	pump	inhibitor.	H2RA	is	histamine-2	receptor	 
antagonist.	NSAID	is	non-steroidal	anti-inflammatory	drug. 
SOURCE:	Shireman,	T.I.,	University	of	Kansas	Medical	Center:	Analysis	of	Kansas	Medicaid	prescription	drug	claims	from	Kansas	Department	of	 
Social	and	Rehabilitation	Services,	2007. 
agents. The most dramatic declines were 
seen in the older antipsychotics (24 per­
cent), anti-ulcer medications (22 percent), 
and anti-inflammatory agents (21 percent). 
Table 4 shows changing mean monthly 
prescription expenditures for each drug 
class, including increases for six of the 
eight classes. In contrast, mean monthly 
expenditures declined for antibiotics and 
anti-ulcer medications, with costs for both 
newer and older drugs in both of these 
classes decreasing. For example, mean 
monthly PPI expenditures declined from 
$130.90 to $118.04 per drug and mean 
monthly H2-antagonist prices declined 
from $60.46 to $28.05. This is likely due 
to generic versions of omeprazole (a PPI) 
and ranitidine (an H2-antagonist) becom­
ing available part-way through the study. 
The largest increase in prescription price 
occurred for the long-acting opioids where 
mean monthly prices increased from 
$171.56 to $310.77, or 81 percent. Although 
prices for older agents generally declined, 
they increased for short-acting opioids and 
antidiabetic agents. 
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In all classes, newer agents accounted 
for a higher percent of expenditures than 
the percentage of prescriptions as shown 
in Figure 1. (Additional information is avail­
able on request from the author.) Antibi­
otics and antidiabetic agents saw the least 
change in the relative composition of newer 
and older agents. For all other groups, 
newer medications contributed dispropor­
tionately to expenditures. For instance, 
newer anti-inflammatory agents accounted 
for 35 percent of the prescriptions in the 
class in the first period, but 54 percent of 
the expenditures. They grew to 52 percent 
of the prescriptions and 74 percent of the 
expenditures by the third period. Long-
acting opioid use grew only slightly from 
9 to 11-12 percent of prescriptions, but 
accounted for a marked increase in the pro­
portion of expenditures (increasing from 
43 to 64 percent). Newer antipsychotics, 
antidepressants, and anti-ulcer medications 
comprised over 70 percent of prescriptions 
and over 90 percent of expenditures in their 
respective markets. Newer anticonvulsants 
grew from 18 to 28 percent of prescriptions 
accompanied by a change from 37 to 53 
percent of expenditures. 
DiSCUSSiOn 
Our purposes were to describe patterns 
of prescription drug use among the Kan­
sas Medicaid disabled population and to 
examine the contribution to Medicaid’s 
expenditures from shifts toward newer 
medications. We found marked shifts 
toward newer medications over a 3-year 
period and disproportionate contributions 
of newer, more expensive medications to 
overall prescription costs for antipsychotics, 
antidepressants, anticonvulsants, anti-ulcer 
medications, anti-inflammatory agents, and 
opioids. These results are quite similar to 
those we reported for the aged Medicaid 
beneficiaries (Shireman et al., 2005). 
The fact that newer medications are com­
monly prescribed and that these agents are 
more expensive to purchase is a familiar 
theme for health care professionals, poli­
cymakers, and the public. However, this 
study quantifies that pattern for specific, 
commonly used medication groups and 
describes the cost impact on Medicaid’s 
pharmacy programs for disabled persons, 
currently the most expensive Medicaid 
enrolled population. Other researchers 
have noted that rising prescription costs 
in Medicaid are attributable in part to the 
prescribing of newer, more expensive 
drugs when older, less-expensive agents 
might often be equally effective (Morden 
and Sullivan, 2005; Soumerai, 2004; Soume­
rai, Majumdar, and Lipton, 2000). Frank et 
al. (2005) explored this trend specifically 
among psychotropic drugs. They showed 
that growth in spending for antipsychotics 
was due to changes in the price and vol­
ume of newer drugs. Medicaid provides 
coverage for nearly 27 percent of all men­
tal health expenditures (Mark and Buck, 
2005), and since the disabled program 
includes persons with severe mental ill­
ness, the present study, in part, reflects 
how those dollars are being spent with 
respect to psychiatric medications. Further, 
regarding Medicaid’s overall spending on 
individual prescription products, they noted 
that newer antipsychotics ranked first, sec­
ond, and eighth, against drugs that would 
be disproportionately used by the disabled 
Medicaid enrollees when compared to 
females, children, and the elderly. Indeed, 
the authors speculated that generous cov­
erage by Medicaid and other insurance 
programs broadened the use of expensive 
medications and resulted in a greater will­
ingness by physicians to prescribe them. 
Soumerai et al. (2000) noted, “…there is 
little doubt that the importance of subopti­
mal prescribing practice (both under- and 
overuse) vastly outweighs the costs of 
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SOURCE:	Shireman,	T.I.,	University	of	Kansas	Medical	Center:	Analysis	of	Kansas	Medicaid	prescription	drug	 
claims	from	Kansas	Department	of	Social	and	Rehabilitation	Services,	2007. 
medications themselves.” Recognizing this clearly expects prescription drug plans to 
potential, several States are currently con­ implement utilization management and 
sidering legislation that limits the ability cost control tools, such as step therapy and 
of pharmaceutical sales representatives to therapeutic interchange. The 2003 Medi­
gather data on physician prescribing prac­ care Prescription Drug, Improvement, and 
tices. Such efforts are intended to curb tar­ Modernization Act legislation and its regu­
geted outreach to certain physicians that lations make clear that a high use of generic 
can result in overprescription of new and medications is a goal for the Part D pro­
expensive brand name drugs (Saul, 2006). gram (Federal Register, 2005). Nationally, 
The 1990 Omnibus Budget Reconcilia­ 2.5 million dually eligible disabled persons 
tion Act (OBRA) prevented State Medicaid transitioned from Medicaid to Medicare 
Programs from imposing restrictive formu­ Part D coverage for prescriptions on Janu­
laries and limited avenues for influencing ary 1, 2006. Generally, Part D prescription 
drug utilization patterns. Many State Med­ drug plans (PDPs) are required to cover all 
icaid Programs have tried to control their or substantially all of the drugs within three 
prescription drug costs through drug uti­ of the classes studied here: antidepres­
lization review, monthly caps on numbers sants, antipsychotics, and anticonvulsants. 
of prescriptions, prior authorization pro­ For the other drug classes studied, PDPs 
grams, and more recently, preferred drug are only required to cover at least two med­
lists, though these programs have had lim­ ications within a pharmacologic class. The 
ited effectiveness (Crowley, Ashner, and implications for expanding generic drug 
Elam, 2005). Under Medicare Part D, CMS use and cost control are unclear. 
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Several limitations of this study should 
be noted, including those that relate to 
the use of administrative claims data for 
research purposes. Although Medicaid 
pharmacy claims are widely considered to 
be reliable, the identification of diagnosis 
codes in administrative data may be more 
accurate for some conditions than for oth­
ers. Expenditure data reflected only Medic­
aid’s contribution and did not include costs 
borne by other payers. As previously noted, 
health outcomes, including quality of life 
and adherence, associated with various 
prescribing options were not examined. 
The study sample reflects a wide breadth of 
types of health conditions and disabilities: 
patterns among subgroups of beneficiaries 
with particular diseases may vary. Finally, 
these data come from a single Midwestern 
State with a relatively open Medicaid for­
mulary during the study period and may 
not reflect the experience of other State 
Medicaid Programs or that of other payers. 
It is also important to note that only drug 
expenditures are reported here. For many 
of these medication classes, newer medi­
cation options may have potential benefits 
in terms of improved tolerability, reduced 
dosing frequency, better adherence, or 
other favorable clinical characteristics. 
Newer medications may also be advocated 
by current practice guidelines, consen­
sus statements, and disease management 
algorithms, and thus be preferred by pre­
scribers. Patients may also have strong 
preferences for newer medications that 
they believe may have better tolerability 
or outcomes. To the extent that clinical 
outcomes may be better with newer, more 
expensive medications than with older, less 
expensive ones for the same condition, 
cost offsets may occur in other parts of the 
health care system due to aborted hospital 
admissions, fewer disease complications, 
or other laudable outcomes. For instance, 
the atypical antipsychotics were considered 
a major advance in psychiatry because of 
lower rates of extra-pyramidal side effects 
that were associated with the older, typi­
cal antipsychotics. This likely fueled the 
rapid adoption of atypical antipsychotics 
and the near obsolescence of the typical 
antipsychotics and may have prevented 
many untoward reactions among persons 
with severe mental illness. More recent 
concerns about weight gain and subse­
quent development of diabetes coupled 
with trials demonstrating little therapeutic 
advantage associated with the atypical anti-
psychotics, however, have raised questions 
about their relative cost effectiveness. It is 
reasonable to assume that certain patients 
would benefit more from the use of atypi­
cal antipsychotics than other patients 
would. It is important to remember, how­
ever, that newer agents often are adopted 
outside the narrow scope of the popula­
tions in whom such clear cost effectiveness 
has been shown; the literature is replete 
with examples of non-selective diffusion of 
innovation (Dai, Stafford, and Alexander, 
2005). Because manufacturers only have 
to demonstrate efficacy relative to place­
bos, clinicians have little guidance in select­
ing cost-effective therapy. Further work 
in evidence-based guidelines can help to
inform clinicians. 
The size and breadth of Part D will give 
it power to inform drug benefit design and 
provide a rich database for postmarket­
ing drug surveillance (Morden and Sul­
livan, 2005). With regard to the findings 
we present, the differential Part D formu­
lary design requirements for some drug 
classes versus others may create a test of 
which cost control strategies are effective 
and appropriate. Carefully designed studies 
that examine the impact of varying Part D 
coverage of key medication classes, such 
as those described here, and medication 
therapy management services on patient 
outcomes would contribute substantially 
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to our knowledge of relative therapeutic
cost effectiveness. 
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